AGIO — Agios Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.99bn
- $1.09bn
- $36.50m
- 48
- 65
- 75
- 67
Annual cashflow statement for Agios Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -327 | 1,605 | -232 | -352 | 674 |
| Depreciation | |||||
| Non-Cash Items | 97.7 | -1,984 | -69.8 | 68.5 | -1,049 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -71 | -36.8 | -16.4 | -19.1 | -19.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -291 | -407 | -309 | -296 | -390 |
| Capital Expenditures | -14.9 | -5.74 | -4.88 | -0.999 | -1.69 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 90.7 | 1,255 | 248 | 241 | 365 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 75.7 | 1,249 | 243 | 240 | 363 |
| Financing Cash Flow Items | 251 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 262 | -766 | 2.35 | 5.43 | 14.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 46.5 | 75.7 | -63.9 | -51.1 | -12 |